Dyne Therapeutics, Inc. (DYN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Dyne and certain of its officers and/or directors have violated federal securities laws.
On January 18, 2022, Dyne issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has placed on clinical hold its Investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.” Dyne reported that it “received a clinical hold letter from the FDA on Friday, January 14, 2022 requesting additional clinical and non-clinical information for DYNE-251” and that “the Company expects to submit to the FDA its response with data from existing and ongoing studies in the second quarter of 2022, and if satisfactory to the FDA, to be dosing patients in a Phase 1/2 multiple ascending dose (MAD) clinical trial of DYNE-251 by mid-2022 in accordance with its current guidance.” On this news, Dyne’s stock price fell $1.17 per share, or 12.59%, to close at $8.12 per share on January 18, 2022.
If you are aware of any facts relating to this investigation or purchased Dyne shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.